140 related articles for article (PubMed ID: 14997052)
21. Impact of a managed-Medicare physical activity benefit on health care utilization and costs in older adults with diabetes.
Nguyen HQ; Ackermann RT; Berke EM; Cheadle A; Williams B; Lin E; Maciejewski ML; LoGerfo JP
Diabetes Care; 2007 Jan; 30(1):43-8. PubMed ID: 17192331
[TBL] [Abstract][Full Text] [Related]
22. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
23. Direct costs of blindness experienced by patients enrolled in managed care.
Frick KD; Walt JG; Chiang TH; Doyle JJ; Stern LS; Katz LM; Dolgitser M; Hendlish SK
Ophthalmology; 2008 Jan; 115(1):11-7. PubMed ID: 17475331
[TBL] [Abstract][Full Text] [Related]
24. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
25. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
Kim MH; Johnston SS; Chu BC; Dalal MR; Schulman KL
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):313-20. PubMed ID: 21540439
[TBL] [Abstract][Full Text] [Related]
26. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
[TBL] [Abstract][Full Text] [Related]
27. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease.
Kaltenboeck A; Johnson SJ; Davis MR; Birnbaum HG; Carroll CA; Tarrants ML; Siderowf AD
Parkinsonism Relat Disord; 2012 May; 18(4):321-6. PubMed ID: 22177623
[TBL] [Abstract][Full Text] [Related]
28. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
29. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
30. Burden of breast cancer with brain metastasis: a French national hospital database analysis.
Benjamin L; Cotté FE; Mercier F; Vainchtock A; Vidal-Trécan G; Durand-Zaleski I
J Med Econ; 2012; 15(3):493-9. PubMed ID: 22304337
[TBL] [Abstract][Full Text] [Related]
31. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
32. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
33. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
35. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Raaijmakers JA; Schellens JH
Breast Cancer Res Treat; 2013 Jun; 139(2):489-95. PubMed ID: 23645005
[TBL] [Abstract][Full Text] [Related]
36. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
37. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
38. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
39. Medical costs associated with metastatic breast cancer in younger, midlife, and older women.
Trogdon JG; Baggett CD; Gogate A; Reeder-Hayes KE; Rotter J; Zhou X; Ekwueme DU; Fairley TL; Wheeler SB
Breast Cancer Res Treat; 2020 Jun; 181(3):653-665. PubMed ID: 32346820
[TBL] [Abstract][Full Text] [Related]
40. Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer.
Williams CP; Azuero A; Kenzik KM; Pisu M; Nipp RD; Bhatia S; Rocque GB
J Natl Compr Canc Netw; 2019 Oct; 17(10):1221-1228. PubMed ID: 31590153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]